TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20508978

Group type: COMPARATOR
Intervention: Community-wide intervention alone (tribe A)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Community-wide intervention with family component (tribes B and C)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Community-wide intervention (tribe A)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: All tribes
Number of subjects: 205
Study: 18251036

Group type: EXPERIMENTAL
Intervention: Thymoglobulin-based CS-avoidance regimen (n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Long-term CS-based regimen with no antibody induction (control group; n = 16)
Number of subjects: 32
Study: 15511603

Group type: EXPERIMENTAL
Intervention: Low-dose 0.25 mg dexamethasone suppression test (LD-DST)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Dermal vasoconstrictor assay (DVVA)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: BclI GG genotype association
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: CAPS scores correlation
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: N363S and BclI GR polymorphisms
Number of subjects: 118

Group type: COMPARATOR
Intervention: Basal plasma cortisol levels
Number of subjects: 118
Study: 12200975

Group type: EXPERIMENTAL
Intervention: PRP/BPBM/GTR
Number of subjects: 18

Group type: COMPARATOR
Intervention: GTR
Number of subjects: 18
Study: 10630494

Group type: EXPERIMENTAL
Intervention: Clarithromycin (CLA) 250 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 16
Study: 8941814

Group type: EXPERIMENTAL
Intervention: Stainless steel crowns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multisurface amalgam restorations
Number of subjects: 0
Study: 1934204

Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories, 100 mg q8hr for five doses
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 50
Study: 6130197

Group type: EXPERIMENTAL
Intervention: Cl2MDP 1600 mg/day orally
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 28617715

Group type: EXPERIMENTAL
Intervention: Rest-pause group (n = 9; 3 sets of 6 repetitions with 80% of 1-repetition maximum (1RM) and 2-minute rest intervals)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional multiple-set group (n = 9; 3 sets of 6 repetitions with 80% of 1-repetition maximum (1RM) and 2-minute rest intervals)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rest-pause group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional multiple-set group
Number of subjects: 18
Study: 29624362

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 530
Study: 26946419

Group type: EXPERIMENTAL
Intervention: Ologen implant (OLO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mitomycin-C (MMC)
Number of subjects: 40
Study: 23823710

Group type: EXPERIMENTAL
Intervention: High-velocity resistance training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low-velocity resistance training
Number of subjects: 46
Study: 21953301

Group type: EXPERIMENTAL
Intervention: Madenci hand massage technique + splint
Number of subjects: 84

Group type: COMPARATOR
Intervention: Splint only
Number of subjects: 84
Study: 18952699

Group type: EXPERIMENTAL
Intervention: Population-based screening study for chronic kidney disease (CKD)
Number of subjects: 6311
Study: 21753727

Group type: EXPERIMENTAL
Intervention: NGX-4010 (capsaicin 8% patch)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control (capsaicin 0.04% wt/wt)
Number of subjects: 302
Study: 16240703

Group type: COMPARATOR
Intervention: Bimosiamose disodium 30 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12091327

Group type: EXPERIMENTAL
Intervention: Lamivudine prophylaxis administered to 13 patients for 1 to 60 days (mean, 15 days) before immunosuppressive treatment and continued for 0.5 to 24 months (mean, 7 months) after initiation of immunosuppression.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (5 patients) who were HBV carriers treated for hematological malignancies without lamivudine.
Number of subjects: 18
Study: 10337288

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide gel used nightly for 2 weeks
Number of subjects: 29
Study: 9005783

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Intravenous administration of Ofloxacin
Number of subjects: 124
Study: 2011615

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7138749

Group type: EXPERIMENTAL
Intervention: 100 mg labetalol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 300 mg labetalol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30328648

Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Zolpidem (0.25 mg/kg)
Number of subjects: 80
Study: 26316551

Group type: EXPERIMENTAL
Intervention: Modified sit-to-stand training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sit-to-stand training with symmetrical foot position (Control)
Number of subjects: 50
Study: 25704750

Group type: EXPERIMENTAL
Intervention: ASP015K (10, 25, 60, 100 mg twice daily; 50 mg once daily)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 24304715

Group type: EXPERIMENTAL
Intervention: läuft. program (multicomponent school-based program including pedometers, competitions, educational lessons, and parental involvement)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: läuft. program
Number of subjects: 100
Study: 20650784

Group type: EXPERIMENTAL
Intervention: Tested preparation (orally disintegrating tablets of pentoxyverine citrate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference preparation (orally disintegrating tablets of pentoxyverine citrate)
Number of subjects: 20
Study: 18087205

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 641
Study: 15728039

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 52

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 52
Study: 12762636

Group type: EXPERIMENTAL
Intervention: Oral administration of 3 capsules (570 mg of iodine)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 1 ml of Lipiodol UF (480 mg of iodine)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intramuscular injection of Lipiodol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral administration of Lipiodol
Number of subjects: 36
Study: 10391813

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 69

Group type: COMPARATOR
Intervention: Intradermal BCG vaccination
Number of subjects: 69
Study: 8911354

Group type: EXPERIMENTAL
Intervention: Nipple valve
Number of subjects: 70

Group type: COMPARATOR
Intervention: Afferent tubular segment
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 1879394

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (30 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 6128313

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Medazepam 10 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30339299

Group type: EXPERIMENTAL
Intervention: Removing task errors by moving the target mid-movement to align with cursor feedback of hand position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enforcing task error by moving the target away from the cursor feedback of hand position by 20-30°
Number of subjects: 0
Study: 27027671

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Palliation of symptoms with oxygen and morphine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Overall comprehension of options
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Treatment according to wishes
Number of subjects: 43
Study: 23362336

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Massage plus guided imagery
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 96

Group type: COMPARATOR
Intervention: No‐treatment control
Number of subjects: 96
Study: 22765260

Group type: EXPERIMENTAL
Intervention: Supplementary fat/protein (CFP) counting
Number of subjects: 42

Group type: COMPARATOR
Intervention: Carbohydrate (CARB) counting
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Normal bolus with CFP counting
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dual-wave bolus with CFP counting
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CFP counting
Number of subjects: 42
Study: 20141275

Group type: EXPERIMENTAL
Intervention: Patients with PD who were more aware of cue-reward relationships
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimally aware patients with PD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study: 18500678

Group type: EXPERIMENTAL
Intervention: 60 mg pioglitazone over nine days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15598942

Group type: EXPERIMENTAL
Intervention: UFT 400 mg/m² for 1 year after surgery
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: UFT for adenocarcinoma patients (n=120)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group for adenocarcinoma patients (n=121)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: UFT for squamous cell carcinoma patients (n=43)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group for squamous cell carcinoma patients
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: UFT for all pT1 patients
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group for all pT1 patients
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: UFT for pT1 adenocarcinoma patients
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: UFT for pT2 patients
Number of subjects: 332
Study: 12027917

Group type: EXPERIMENTAL
Intervention: MOSES educational program
Number of subjects: 242
Study: 9475816

Group type: EXPERIMENTAL
Intervention: Regular team interventions involving a pharmacist, physician, nurses, undernurses, and nurse's aides discussing drug therapy.
Number of subjects: 15
Study: 8584609

Group type: EXPERIMENTAL
Intervention: 25 mg NNC 01-0687
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 45 mg NNC 01-0687 administered t.i.d. for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: NNC 01-0687 (active)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NNC 01-0687
Number of subjects: 0
Study: 2223339

Group type: EXPERIMENTAL
Intervention: lignocaine 1.5 mg kg‐1 i.v. 1 min before laryngoscopy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: lignocaine 1.5 mg kg‐1 i.v. 2 min before laryngoscopy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: lignocaine 1.5 mg kg‐1 i.v. 3 min before laryngoscopy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no lignocaine)
Number of subjects: 45
Study: 372525

Group type: EXPERIMENTAL
Intervention: Naproxen (750 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (3.6 gm/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 31881545

Group type: EXPERIMENTAL
Intervention: Nomogram based on clinical factor and biomarkers (degree of resection, E-cadherin, Ki-67, VEGFA)
Number of subjects: 201
Study: 28535550

Group type: EXPERIMENTAL
Intervention: High voltage PRF
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard voltage PRF
Number of subjects: 60
Study: 25552421

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study: 24088361

Group type: EXPERIMENTAL
Intervention: SR-IFN-α (9, 18, 27, and 36 MIU subcutaneous doses)
Number of subjects: 24
Study: 21850272

Group type: EXPERIMENTAL
Intervention: Intranasal GHRH (600 µg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19726914

Group type: EXPERIMENTAL
Intervention: Exercise intervention (stretching, muscle strengthening, and walking exercise)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 21
Study: 17596044

Group type: EXPERIMENTAL
Intervention: 1.5% carboxy‐methyl cellulose sodium paste containing 2% barium sulfate
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 5.5% potato starch containing 2% barium sulfate
Number of subjects: 107

Group type: COMPARATOR
Intervention: 3% commercial barium paste
Number of subjects: 107
Study: 14693410

Group type: EXPERIMENTAL
Intervention: InnoLet
Number of subjects: 79

Group type: COMPARATOR
Intervention: vial/syringe
Number of subjects: 79
Study: 11157327

Group type: COMPARATOR
Intervention: 1046 kJ energy load supplement
Number of subjects: 25

Group type: COMPARATOR
Intervention: 2092 kJ energy load supplement
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fat-rich supplement (1046 kJ)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich supplement (1046 kJ)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9640150

Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia (EA) with lumbar extradural block and lidocaine (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: General anaesthesia (GA) maintained with 1.5‐2.5% sevoflurane and 66% nitrous oxide in oxygen (n = 11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups (EA and GA)
Number of subjects: 22
Study: 8092581

Group type: EXPERIMENTAL
Intervention: Cryoanesthesia using freon spray for venepuncture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional venepuncture
Number of subjects: 80
Study: 2663609

Group type: EXPERIMENTAL
Intervention: Glucagon and insulin infusion (1 mg glucagon and 10 units insulin twice daily for one week)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 98
Study: 22216499

Group type: EXPERIMENTAL
Intervention: 375 mg theophylline orally
Number of subjects: 14

Group type: COMPARATOR
Intervention: 200 microg salbutamol by pressurized aerosol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: theophylline
Number of subjects: 14
Study: 31733754

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study: 28515105

Group type: EXPERIMENTAL
Intervention: Methylation testing using SHOX2 and SEPT9 DNA in plasma
Number of subjects: 649
Study: 25976606

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 23661283

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Trazodone (25 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 21740564

Group type: EXPERIMENTAL
Intervention: 2-week disease-related expressive writing procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard writing task (neutral writing condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empty control condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral writing condition (writing about facts regarding heart disease and its treatment)
Number of subjects: 0
Study: 19302743

Group type: EXPERIMENTAL
Intervention: High-angle group (bifurcation angle >= 60 degrees)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Low-angle group (bifurcation angle < 60 degrees)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: With-FKBI group (final kissing balloon inflation)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Without-FKBI group (no final kissing balloon inflation)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Without-FKBI group
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: High-angle group
Number of subjects: 212

Group type: COMPARATOR
Intervention: Low-angle group
Number of subjects: 212
Study: 17011781

Group type: EXPERIMENTAL
Intervention: Posterior-stabilized (PS) insert
Number of subjects: 47

Group type: COMPARATOR
Intervention: Concave insert
Number of subjects: 47

Group type: COMPARATOR
Intervention: Flat insert
Number of subjects: 47
Study: 14692296

Group type: EXPERIMENTAL
Intervention: Nutritional interventions for prevention of type 2 diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional interventions
Number of subjects: 0
Study: 10609980

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 30
Study: 7634784

Group type: EXPERIMENTAL
Intervention: Potent topical corticosteroid (betamethasone‐17‐valerate) applied 2x daily for 7 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vehicle applied 2x daily for 7 days
Number of subjects: 16
Study: 1849392

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 22

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 22
Study: 6958486

Group type: EXPERIMENTAL
Intervention: Budesonide given intranasally as an aerosol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) given as an aerosol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) given as a powder
Number of subjects: 22
Study: 6539997

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cyclophosphamide 1 Gm/M2 each month for six months; cis-platinum 100 mg/M2 each month for four months; combination chemotherapy (CISCA) for one patient)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Expectant follow-up
Number of subjects: 70
Study: 30077569

Group type: EXPERIMENTAL
Intervention: 2.0 mg aflibercept
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 616
Study: 26722854

Group type: EXPERIMENTAL
Intervention: Progesterone (with or without hypothermia)
Number of subjects: 107
Study: 24317704

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 23362673

Group type: EXPERIMENTAL
Intervention: Moderate physical exercise (group 2)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: High physical exercise (group 3)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Resting condition (group 1)
Number of subjects: 3
Study: 20970079

Group type: EXPERIMENTAL
Intervention: REAL MEN intervention (30-hour jail/community-based intervention)
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Use of CBO services
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: REAL MEN intervention
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: CBO visitors
Number of subjects: 552

Group type: COMPARATOR
Intervention: All participants (including control)
Number of subjects: 552
Study: 18564001

Group type: EXPERIMENTAL
Intervention: Training for perfect breastfeeding
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoclopramide (10 mg/dose every 8 hours for 15 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (for 15 days)
Number of subjects: 20
Study: 16001749

Group type: EXPERIMENTAL
Intervention: 50 microg of misoprostol
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 100 microg of misoprostol
Number of subjects: 95
Study: 12462537

Group type: EXPERIMENTAL
Intervention: Progressive addition lenses
Number of subjects: 469

Group type: COMPARATOR
Intervention: Single vision lenses
Number of subjects: 469
Study: 10683591

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7604668

Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 13
Study: 2029409

Group type: EXPERIMENTAL
Intervention: estramustine phosphate
Number of subjects: 195

Group type: COMPARATOR
Intervention: diethylstilbestrol
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: DNA studies
Number of subjects: 195
Study: 7032273

Group type: EXPERIMENTAL
Intervention: 200 micrograms trivalent chromium in 5 ml water (Cr)
Number of subjects: 23

Group type: COMPARATOR
Intervention: 5 ml plain water (W)
Number of subjects: 23
Study: 30777903

Group type: EXPERIMENTAL
Intervention: Cooled Radiofrequency Ablation (C-RFA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Traditional Radiofrequency Ablation (T-RFA)
Number of subjects: 43
Study: 28720372

Group type: EXPERIMENTAL
Intervention: Pneumatic lithotripsy
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ultrasonic lithotripsy
Number of subjects: 180
Study: 27101684

Group type: EXPERIMENTAL
Intervention: NBI target biopsy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Regular biopsy
Number of subjects: 156
Study: 24196948

Group type: EXPERIMENTAL
Intervention: Combination of eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) with valproic acid
Number of subjects: 43

Group type: COMPARATOR
Intervention: Single valproic acid
Number of subjects: 43
Study: 22233788

Group type: EXPERIMENTAL
Intervention: Low load exercises targeting the gluteal muscle group (GM-P)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Whole-body vibration protocol (WBV-P)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No-warm-up condition (CON)
Number of subjects: 22
Study: 19772514

Group type: EXPERIMENTAL
Intervention: Regular nebulized glucocorticoid (400 microg beclomethasone bid) plus prn bronchodilator (2500 microg salbutamol)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: prn nebulized bronchodilator/glucocorticoid combination (800 microg beclomethasone/1600 microg salbutamol)
Number of subjects: 276

Group type: COMPARATOR
Intervention: prn salbutamol (2500 microg)
Number of subjects: 276
Study: 17504586

Group type: EXPERIMENTAL
Intervention: Collaborative care model with facilitated self-help programme
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 105
Study: 15801580

Group type: EXPERIMENTAL
Intervention: Behavioral counseling program consisting of seven sessions over 6 months.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Measures-only control condition.
Number of subjects: 150